Jake Chabon

Developing novel blood-based cancer diagnostic assays | CEO @ForesightDx | former PhD @StanfordMed | #ctdna #LiquidBiopsy #MRD

[Foresight Diagnostics Inc. @ForesightDx]

We are presenting four oral presentations and two posters at #ASH23, with new data on PhasED-Seq's earlier and more accurate MRD detection vs. PET/CT.
It’s time to rethink response assessment in clinical trials.

https://t.co/EDWlwOAHT1

#ASH23

[Foresight Diagnostics Inc. @ForesightDx]

We are excited to announce that we closed an oversubscribed Series B financing round of $58.75M. The financing was led by @ForesiteCapital with participation from @CivilizationVC , @BluebirdLifeSci, @pearvc , @agent_capital, @Stanford, @CUSystem.

https://t.co/PwhpbRU7hG

[Jake Chabon @JakeChabon]

Important @Nature paper & further evidence for oncogenicity of phased variants (PVs) as driving events in #cancer. PV analysis revealed super-enhancer hypermutation in 92% of #DLBCL samples. https://t.co/06JmYzzTCK

#lymphoma #cancerscreening #MRD @ForesightDx @HKhiabanianin

[Shahram Seyedin-Noor @ShahramSN]

I told the founding team at @ForesightDx that we’re builders at @CivilizationVC. And I meant it! :)

Awesome new offices in Colorado.

Ready to conquer #Cancer thru better #diagnostics

@AshAlizadeh @JakeChabon @max_diehn

@themasap

[Jake Chabon @JakeChabon]

Very exciting to finally see this in print! Great work @mohamshah, @emham, and everyone else on the team who contributed to this work! Looking forward to bringing this assay to patients at
@ForesightDx.

[Ash Alizadeh, MD/PhD 🇺🇸 @AshAlizadeh]

Excited to share our new study introducing #EPICSeq out today @NatureBiotech!
https://t.co/o8YY1IH1Sy

[Foresight Diagnostics Inc. @ForesightDx]

Detect a potential cancer relapse 200 days sooner. The PhasED-Seq platform detects residual tumor DNA at levels below current testing: https://t.co/0H4SaKRJ4b

#cancer #tumor #lymphoma #LiquidBiopsy #relapse

[Foresight Diagnostics Inc. @ForesightDx]

We were recently chosen to take part in a NSCLC research summit with AstraZeneca and wanted to share some relevant data about our work in lung cancer.

Check out the poster originally presented at ASCO last year: https://t.co/2zKtadJXMh

#NSCLC #liquidbiopsy #MRD

[Jake Chabon @JakeChabon]

I am honored Dr. Horning has joined our team. She brings significant experience and a shared belief that more sensitive #MRD assays can improve clinical decision making. We look forward to her contributions to @ForesightDx as we realize our vision for improved patient care.

[Foresight Diagnostics Inc. @ForesightDx]

We’re pleased to announce the addition of Sandra Horning, MD to the Foresight Diagnostics Scientific Advisory Board. A seasoned clinician and biopharmaceutical executive, Dr Horning brings a keen interest in clinical MRD utilization.
https://t.co/j1dnJKOJDI
#lymphoma

[Foresight Diagnostics Inc. @ForesightDx]

Our PhasED-Seq #ctDNA liquid biopsy strongly correlates with standard of care CT imaging in #DLBCL patients and remarkably identifies treatment response to acalabrutinib in only 7 days.

Read the #ASH21 abstract (524) here: https://t.co/MQlu5oTz2D

@AshAlizadeh

[Foresight Diagnostics Inc. @ForesightDx]

Our PhasED-Seq #ctDNA platform’s transformative potential to improve #MRD detection, along with research led by our co-founder Dr. David Kurtz, was the subject of @landau_lab and @AlexandrePCheng’s recent review paper in Med.

Read more: https://t.co/I8eeWtedBz

[Foresight Diagnostics Inc. @ForesightDx]

We’re honored to be named a finalist for the CBSA Rising Star award and look forward to seeing members of the Colorado life science community at the 2021 Colorado BioScience Innovation Forum and Annual Awards Celebration.

https://t.co/LSlWnS90cR

#CoBioScience @cobioscience

[Foresight Diagnostics Inc. @ForesightDx]

.@CLPmag featured us in a deep dive on PhasED-Seq, our #ctDNA #MRD detection platform. Co-founder/CEO, @JakeChabon PhD discusses PhasED-Seq’s superior sensitivity over existing #LiquidBiopsy assays and its potential to improve B cell #lymphoma management.

https://t.co/yA3mVCQIv1

[Foresight Diagnostics Inc. @ForesightDx]

A major advance in 1st line #DLBCL care and the first in 20 years was reported in the POLARIX trial showing improved PFS vs. standard of care. Along with our PhasED-Seq #ctDNA platform that detects #MRD, we are improving the lives of #lymphoma patients.

https://t.co/F61WHu9Vba

[Ash Alizadeh, MD/PhD 🇺🇸 @AshAlizadeh]

Delighted to share our new study https://t.co/o2QcGsVNGQ introducing PhasED-Seq out today @NatureBiotech.

[Foresight Diagnostics Inc. @ForesightDx]

Foresight co-founders @max_diehn MD/PhD and @AshAlizadeh MD/PhD in @GenomeWeb explain what differentiates PhasED-Seq from existing #MRD approaches as well as future #PrecisionMedicine applications our #ctDNA platform could enable.

Access the article here: https://t.co/nArdcsex7s

[Foresight Diagnostics Inc. @ForesightDx]

We have been featured in a story by @BioWorldMedTech. Our co-founder and CEO, @JakeChabon, discusses findings from our recent @NatureBiotech publication and the potential of our PhasED-Seq #ctDNA platform in cancer surveillance and diagnostics.

[Jake Chabon @JakeChabon]

The paper describing PhasED-Seq, the key #ctDNA technology enabling our ultra-sensitive #liquidbiopsy #MRD platform was published today in @NatureBiotech! The paper has been a labor of love & we are so grateful to the patients and their families for participating in this study.

[Foresight Diagnostics Inc. @ForesightDx]

Today we published data demonstrating the utility of our PhasED-Seq #ctDNA platform for detecting #MRD in B-cell #lymphoma patients in @NatureBiotech. Our highly sensitive approach finds relapses that current methods overlook.

For more details see our PR: https://t.co/hdOXeLGMkD

[Foresight Diagnostics Inc. @ForesightDx]

We are presenting exciting new data on the performance of our #MRD platform in #DLBCL patients at @icmlugano this Sunday. The talk will introduce PhasED-Seq, our proprietary technology that enables #ctDNA detection down to parts-per-million levels! https://t.co/BJtFybOxt5

[Foresight Diagnostics Inc. @ForesightDx]

Presentations describing Foresight's novel #ctDNA assay for #MRD detection in #lymphoma (Abstract #7565) and #lungcancer (Abstract #8518) are live at #ASCO21! If redirected, try opening the link in an incognito window.

https://t.co/4r72bnLd0E
https://t.co/VtHZJ4tOFe

[Pejman Nozad @pejmannozad]

Finally we can reveal this!

100-times more sensitive than existing liquid biopsy approaches which improves the lives of cancer patients.

We are so excited to announce our investment in Foresight!
@ForesightDx @CivilizationVC @BluebirdLifeSci @pearvc